PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2014-08-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02163161
- Locations
- π§πͺ
Pfizer Investigational Site, Brussels, Belgium
Study to Estimate the Relative Bioavailability Compared to Commercial Extended-release Tablet Formulation and the Effects of Food Or Sprinkling on Applesauce for Fesoterodine Sustained-release Beads-in-capsule Formulations in Healthy Adult Volunteers
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT02160158
- Locations
- π§πͺ
Pfizer Clinical Research Unit, Brussels, Belgium
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2014-06-09
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 158
- Registration Number
- NCT02159066
- Locations
- πΊπΈ
Doris Stein Research Center Building, Los Angeles, California, United States
πΊπΈOHSU Center for Health and Healing 2, Portland, Oregon, United States
πΊπΈUniversity of California Los Angeles, Los Angeles, California, United States
Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 111
- Registration Number
- NCT02156895
- Locations
- π°π·
Pfizer Tower, Seoul, Korea, Republic of
A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT02151617
- Locations
- πΊπΈ
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2018-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 112
- Registration Number
- NCT02147587
- Locations
- πΊπΈ
Rheumatology Consultants, PLLC, Knoxville, Tennessee, United States
πΊπΈBaylor Research Institute Arthritis Care and Research Center, Dallas, Texas, United States
πΊπΈCenter for Arthritis and Rheumatic Diseases, Miami, Florida, United States
Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT02146378
Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT02142920
- Locations
- π¬π§
Pfizer Investigational Site, Ruddington Fields, Nottingham, United Kingdom
Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
- Conditions
- Advanced Breast Cancer (Female)
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT02142868
- Locations
- πΊπΈ
Presence Saint Joseph Hospital, Chicago, Illinois, United States
πΊπΈPresence Infusion Care - Skokie, Skokie, Illinois, United States
πΊπΈSKCCC at Johns Hopkins, The Harry and Jeannette Weinberg Building, Baltimore, Maryland, United States
A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5
- Registration Number
- NCT02138500
- Locations
- πΊπΈ
New Haven Clinical Research Unit, New Haven, Connecticut, United States
πΊπΈAnlyan Center, New Haven, Connecticut, United States
πΊπΈYale University School of Medicine, New Haven, Connecticut, United States